REPORT HIGHLIGHT
Artificial Intelligence In Drug Repurposing Market size was valued at US$ 990.98 Million in 2024, expanding at a CAGR of 20.10% from 2025 to 2032.
Artificial Intelligence in Drug Repurposing involves using advanced computational systems to discover new therapeutic applications for existing drugs by analyzing large and complex biomedical datasets. It applies technologies such as machine learning, deep learning, and natural language processing to identify hidden relationships between drugs, biological targets, and diseases. Governments and regulatory bodies around the world are increasingly recognizing and supporting this shift: regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have issued joint guiding principles for the safe and responsible use of AI in drug development to promote innovation while ensuring patient safety.
These AI-powered approaches accelerate the drug discovery process, lower development costs, and increase the likelihood of identifying effective treatment candidates. By automating data analysis and hypothesis generation, AI enhances research efficiency and supports better decision-making within pharmaceutical and biotechnology organizations. Additionally, artificial intelligence in drug repurposing enables faster responses to unmet medical needs and promotes more accessible, data-driven, and cost-effective drug development strategies.
Artificial Intelligence In Drug Repurposing Market- Market Dynamics
Rising Adoption of Artificial Intelligence and Machine Learning in Pharmaceutical Research and Development
The increasing adoption of artificial intelligence (AI) and machine learning (ML) in pharmaceutical research and development (R&D) reflects the growing integration of advanced computational models into drug discovery and development processes to enhance efficiency and outcomes. These technologies enable the analysis of vast and complex biomedical datasets—such as genomic information, clinical trial data, and scientific literature—to identify novel drug–disease relationships with greater precision. In AI-driven drug repurposing, these capabilities support predictive modeling, target identification, and the rapid screening of existing drug libraries for new therapeutic applications. As a result, pharmaceutical companies can shorten development timelines, reduce R&D costs, and improve decision-making in early-stage research. Additionally, AI and ML facilitate collaboration across digital research platforms by enabling seamless integration of data from multiple sources. They also allow continuous model refinement through real-world evidence and experimental data, strengthening analytical accuracy over time.
Regulatory trends further reinforce this momentum. According to the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER), more than 500 drug-related submissions incorporating AI were recorded between 2016 and 2023, demonstrating a significant rise in AI adoption across the drug development lifecycle. Moreover, the FDA issued draft guidance in 2025 outlining recommendations for the responsible use of AI in regulatory decision-making for drugs and biological products. This initiative highlights the agency’s proactive approach to supporting innovation while upholding rigorous standards for safety and efficacy. Together, these developments underscore strong regulatory and institutional support for integrating AI and ML into pharmaceutical R&D. They also reflect broader industry trends toward data-driven technologies that accelerate drug repurposing, enhance analytical precision, and optimize R&D strategies. Consequently, AI-enabled approaches are emerging as scalable, reliable, and cost-effective solutions for identifying new therapeutic uses and addressing unmet medical needs.
Artificial Intelligence In Drug Repurposing Market- Segmentation Analysis:
The Global Artificial Intelligence in Drug Repurposing Market is segmented by Therapeutic Area, Drug Type, End User, Deployment Mode, and Region.
The Artificial Intelligence (AI) in Drug Repurposing market is segmented by therapeutic area into Oncology, Neurology, and Cardiovascular Diseases, with Oncology accounting for a substantial share. This dominance is largely attributed to AI’s ability to accelerate the identification of new therapeutic applications for existing cancer drugs. By analyzing vast datasets, including genomic information, clinical trial outcomes, real-world evidence, and molecular interaction profiles, AI-powered algorithms and predictive models significantly reduce the time required to identify viable treatment options. Machine learning techniques enhance target identification, biomarker discovery, and candidate prioritization, thereby streamlining research workflows and improving R&D productivity. Shortened discovery timelines not only reduce development costs but also enable faster access to potentially life-saving therapies for patients. The urgency of innovation in oncology is reinforced by government-backed statistics. According to the World Health Organization (WHO), an estimated 20 million new cancer cases and 9.7 million cancer-related deaths were reported globally in 2022, with approximately 53.5 million people living within five years of a cancer diagnosis. Similarly, the U.S. National Cancer Institute (NCI) projects continued growth in global cancer incidence over the coming decades, underscoring the critical need for advanced, technology-driven drug development strategies such as AI-enabled repurposing.
Based on drug type, the market is categorized into Small Molecule Drugs and Biologics, with Small Molecule Drugs holding the largest market share. This leadership position is driven by their broad therapeutic applicability, well-established safety profiles, and the availability of extensive historical and clinical datasets. AI algorithms can efficiently analyze chemical structures, predict drug–target interactions, and uncover novel therapeutic indications using existing pharmacological and molecular data. Compared with de novo drug discovery, repurposing small molecules through AI significantly reduces time, risk, and cost, enabling faster clinical translation. The scalability of AI-driven computational screening and modeling further enhances efficiency across multiple therapeutic areas. Government data further supports this segment’s strength. For example, the U.S. Food and Drug Administration (FDA) reports that small molecule drugs account for the majority of approved new molecular entities in recent years, reflecting their continued importance in pharmaceutical development. In addition, data from the U.S. National Library of Medicine indicates that PubMed indexes over 23 million biomedical citations, with hundreds of thousands of new publications added annually, while government health agencies estimate that more than 80% of healthcare data is unstructured. This expanding volume of structured and unstructured clinical data strengthens AI training capabilities and reinforces the growing role of small molecules in AI-driven drug repurposing initiatives.
Artificial Intelligence In Drug Repurposing Market- Geographical Insights
The Artificial Intelligence in Drug Repurposing market exhibits significant regional variation, shaped by differences in pharmaceutical R&D infrastructure, healthcare systems, regulatory environments, and levels of AI adoption. North America remains a dominant force, accounting for over 40% of the global AI-driven drug repurposing market, supported by a mature pharmaceutical industry, advanced digital health infrastructure, and strong government backing for AI research and healthcare innovation. Europe is experiencing steady growth, supported by increasing investments in pharmaceutical research, regulatory frameworks that promote responsible AI deployment, and the integration of interoperable clinical, genomic, and molecular data systems. Collaborative research programs and cross-border initiatives further contribute to regional expansion.
In the Asia-Pacific region, rapid growth is driven by increasing government support for healthcare digitalization, rising pharmaceutical R&D activities, and large patient populations. Countries like China, India, Japan, and South Korea are emerging as key contributors due to expanding AI research labs, biotech partnerships, and supportive policy frameworks that prioritize AI in life sciences. Meanwhile, Latin America, the Middle East, and Africa are gradually strengthening their presence in the market. Improvements in clinical research infrastructure, increasing access to molecular and clinical datasets, and growing awareness of AI-enabled drug repurposing technologies are supporting steady adoption across these regions.
United States Healthcare Virtual Assistant Market – Country Insights
The United States Artificial Intelligence in Drug Repurposing market is progressing steadily, supported by a well-established pharmaceutical and biotechnology ecosystem and the expanding adoption of AI-driven drug discovery platforms. Research institutions, biotech companies, and pharmaceutical firms are increasingly leveraging artificial intelligence to identify new therapeutic applications for existing drugs, streamline R&D processes, and accelerate clinical development timelines. The involvement of leading technology providers, combined with regulatory encouragement for AI-enabled drug development, is further strengthening market growth. Additionally, the industry’s focus on improving operational efficiency, reducing development costs, and expediting time-to-market is driving the widespread adoption of AI-based drug repurposing solutions across the U.S. pharmaceutical sector.
In parallel, international government initiatives highlight the broader momentum behind AI-driven drug discovery. For example, the UK government has announced support for the OpenBind consortium, which aims to generate more than 500,000 experimental protein–ligand complex structures and binding affinity measurements over five years—representing a 20-fold increase compared with the total volume of publicly available data generated over the past five decades. Backed by government funding and strategic partnerships, this initiative seeks to expand high-quality biomedical datasets and accelerate AI-enabled drug research and development.
Artificial Intelligence In Drug Repurposing Market- Competitive Landscape:
The Artificial Intelligence in Drug Repurposing market is moderately concentrated, with several leading pharmaceutical, biotechnology, and AI-focused technology companies shaping the competitive landscape. Key players include IBM Watson Health, Exscientia, Insilico Medicine, Healx, BenevolentAI, Recursion Pharmaceuticals, Atomwise, Evotec, BioAge Labs, Cyclica, Schrödinger, and In Silico Trials. These companies compete by offering AI-powered platforms designed to identify new therapeutic applications for existing drugs, streamline research and development processes, predict drug–target interactions, and accelerate clinical development timelines. Competitive differentiation is driven by capabilities such as deep learning–based drug discovery, large-scale biomedical data analytics, integration with proprietary and public research databases, and cloud-enabled computational platforms. Such advancements enable faster, more efficient, and cost-effective drug repurposing strategies. For instance, in 2023, Exscientia entered into a multi-target collaboration with Merck KGaA, leveraging its AI-driven drug discovery platform to accelerate the design of novel therapeutics. The agreement included an upfront payment of USD 20 million, with potential milestone payments exceeding USD 670 million. In 2024, Exscientia further strengthened its platform capabilities through a partnership with Amazon Web Services (AWS), facilitating cloud-based computational drug design and large-scale data analytics.
Market growth is largely driven by increasing demand for efficient, data-driven, and AI-enabled drug repurposing solutions, particularly in high-need therapeutic areas such as oncology and rare diseases. Companies are continuously enhancing their platforms with advanced predictive modeling, deep learning algorithms, and scalable cloud-based deployments to meet the growing demand for faster, more precise, and cost-effective identification of new therapeutic uses for existing drugs.
Recent Developments:
-
In November 2024, Recursion Pharmaceuticals completed a business combination with Exscientia, creating a unified AI-powered drug discovery platform that integrates both companies’ technologies and pipelines. The combined entity includes more than 10 clinical and preclinical programs and aims to reduce discovery timelines and costs through iterative, AI-driven research cycles.
-
In July 2024, Insilico Medicine announced a collaboration with Inimmune to leverage its proprietary AI platform, Chemistry42, to accelerate the discovery and development of next-generation immunotherapeutics. This partnership marks a strategic expansion of Insilico’s AI-based drug design capabilities into new therapeutic areas and reinforces the growing role of artificial intelligence in optimizing drug candidates.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG REPURPOSING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Cyclica Inc.
- BioAge Labs, Inc.
- BostonGene Corporation
- Insilico Medicine, Inc.
- Healx Ltd.
- Ignota Labs Ltd.
- Atomwise, Inc.
- Ginkgo Bioworks Holdings, Inc.
- United Therapeutics Corporation
- Recursion Pharmaceuticals, Inc.
- TxGNN, Inc.
- Exscientia plc
- BioXcel Therapeutics, Inc.
- BenevolentAI Limited
- Melior Discovery, Inc.
- Others
GLOBALARTIFICIAL INTELLIGENCE IN DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032
- Metabolic Disorders
- Oncology
- Rare Diseases
- Infectious Diseases
- Neurology
- Immunology
- Cardiovascular Diseases
- Others
GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG REPURPOSING MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032
- Peptides
- Vaccines
- Small Molecules
- Biologics
- Others
GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG REPURPOSING MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032
- Healthcare Providers
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs)
- Others
GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG REPURPOSING MARKET, BY DEPLOYMENT MODE- MARKET ANALYSIS, 2019 - 2032
GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG REPURPOSING MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Artificial Intelligence In Drug Repurposing Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Artificial Intelligence In Drug Repurposing Market Snippet by Therapeutic Area
2.1.2. Artificial Intelligence In Drug Repurposing Market Snippet by Drug Type
2.1.3. Artificial Intelligence In Drug Repurposing Market Snippet by End User
2.1.4. Artificial Intelligence In Drug Repurposing Market Snippet by Deployment Mode
2.1.5. Artificial Intelligence In Drug Repurposing Market Snippet by Country
2.1.6. Artificial Intelligence In Drug Repurposing Market Snippet by Region
2.2. Competitive Insights
3. Artificial Intelligence In Drug Repurposing Key Market Trends
3.1. Artificial Intelligence In Drug Repurposing Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Artificial Intelligence In Drug Repurposing Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Artificial Intelligence In Drug Repurposing Market Opportunities
3.4. Artificial Intelligence In Drug Repurposing Market Future Trends
4. Artificial Intelligence In Drug Repurposing Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Artificial Intelligence In Drug Repurposing Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Artificial Intelligence In Drug Repurposing Market Landscape
6.1. Artificial Intelligence In Drug Repurposing Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Artificial Intelligence In Drug Repurposing Market – By Therapeutic Area
7.1. Overview
7.1.1. Segment Share Analysis, By Therapeutic Area, 2024&2032 (%)
7.1.2. Metabolic Disorders
7.1.3. Oncology
7.1.4. Rare Diseases
7.1.5. Infectious Diseases
7.1.6. Neurology
7.1.7. Immunology
7.1.8. Cardiovascular Diseases
7.1.9. Others
8. Artificial Intelligence In Drug Repurposing Market – By Drug Type
8.1. Overview
8.1.1. Segment Share Analysis, By Drug Type, 2024&2032 (%)
8.1.2. Peptides
8.1.3. Vaccines
8.1.4. Small Molecules
8.1.5. Biologics
8.1.6. Others
9. Artificial Intelligence In Drug Repurposing Market – By End User
9.1. Overview
9.1.1. Segment Share Analysis, By End User, 2024&2032 (%)
9.1.2. Healthcare Providers
9.1.3. Academic & Research Institutes
9.1.4. Pharmaceutical & Biotechnology Companies
9.1.5. Contract Research Organizations (CROs)
9.1.6. Others
10. Artificial Intelligence In Drug Repurposing Market – By Deployment Mode
10.1. Overview
10.1.1. Segment Share Analysis, By Drug Type, 2024&2032 (%)
10.1.2. On-premises
10.1.3. Cloud-based
11. Artificial Intelligence In Drug Repurposing Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2024&2032 (%)
11.2. North America
11.2.1. Overview
11.2.2. Artificial Intelligence In Drug Repurposing Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.2.4. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.2.5. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.2.6. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.2.7. North America Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. Artificial Intelligence In Drug Repurposing Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.3.6. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.7. Europe Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.3.9. UK
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.9.3. UK Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.3.9.4. UK Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.3.9.5. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.9.6. UK Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.3.10. France
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.10.3. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.3.10.4. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.3.10.5. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.10.6. France Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.3.11. Italy
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.11.3. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.3.11.4. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.3.11.5. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.11.6. Italy Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.3.12. Spain
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.12.3. Spain Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.3.12.4. Spain Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.3.12.5. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.12.6. Spain Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.3.13. The Netherlands
11.3.13.1. Overview
11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.13.3. The Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.3.13.4. The Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.3.13.5. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.13.6. The Netherlands Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.3.14. Sweden
11.3.14.1. Overview
11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.14.6. Sweden Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.3.15. Russia
11.3.15.1. Overview
11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.15.3. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.3.15.4. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.3.15.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.15.6. Russia Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.3.16. Poland
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.16.3. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.3.16.4. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.3.16.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.16.6. Poland Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.3.17. Rest of Europe
11.3.17.1. Overview
11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.17.3. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.3.17.4. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.3.17.5. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.17.6. Rest of the Europe Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. Artificial Intelligence In Drug Repurposing Key Manufacturers in Asia Pacific
11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.4.4. APACMarket Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.4.5. APACMarket Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.4.6. APACMarket Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4.7. APACMarket Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.4.8. China
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.8.3. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.4.8.4. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.4.8.5. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4.8.6. China Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.4.9. India
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.9.3. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.4.9.4. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.4.9.5. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4.9.6. India Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.4.13. Indonesia
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.13.3. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.4.13.4. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.4.13.5. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4.13.6. Indonesia Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.4.14. Thailand
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.14.3. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.4.14.4. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.4.14.5. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4.14.6. Thailand Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.15.3. PhilippinesMarket Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.4.15.4. PhilippinesMarket Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.4.15.5. PhilippinesMarket Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4.15.6. PhilippinesMarket Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.4.16. Rest of APAC
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.16.3. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.4.16.4. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.4.16.5. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4.16.6. Rest of APAC Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.5. Latin America (LATAM)
11.5.1. Overview
11.5.2. Artificial Intelligence In Drug Repurposing Key Manufacturers in Latin America
11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.5.4. LATAMMarket Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.5.5. LATAMMarket Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.5.6. LATAMMarket Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.5.7. LATAMMarket Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.6. Middle East and Africa (MEA)
11.6.1. Overview
11.6.2. Artificial Intelligence In Drug Repurposing Key Manufacturers in Middle East and Africa
11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.6.4. MEAMarket Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.6.5. MEAMarket Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.6.6. MEAMarket Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.6.7. MEAMarket Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.10.3. IsraelMarket Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.6.10.4. IsraelMarket Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.6.10.5. IsraelMarket Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.6.10.6. IsraelMarket Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
11.6.14. Rest of MEA
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.14.3. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
11.6.14.4. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
11.6.14.5. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.6.14.6. Rest of MEA Market Size and Forecast, By Deployment Mode , 2019 - 2032 (US$ Million)
12. Key Vendor Analysis- Artificial Intelligence In Drug Repurposing Industry
12.1. Competitive Benchmarking
12.1.1. Competitive Dashboard
12.1.2. Competitive Positioning
12.2. Company Profiles
12.2.1. Cyclica Inc.
12.2.2. BioAge Labs, Inc.
12.2.3. BostonGene Corporation
12.2.4. Insilico Medicine, Inc.
12.2.5. Healx Ltd.
12.2.6. Ignota Labs Ltd.
12.2.7. Atomwise, Inc.
12.2.8. Ginkgo Bioworks Holdings, Inc.
12.2.9. United Therapeutics Corporation
12.2.10. Recursion Pharmaceuticals, Inc.
12.2.11. TxGNN, Inc.
12.2.12. Exscientia plc
12.2.13. BioXcel Therapeutics, Inc.
12.2.14. BenevolentAI Limited
12.2.15. Melior Discovery, Inc.
12.2.16. Others
13. 360 Degree AnalystView
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
